Pharmaceutical
Biopharmaceutical
Manufacturing

Bristol-Myers Squibb

$49.12
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.41 (-0.83%) Today
-$0.07 (-0.14%) After Hours

Why Robinhood?

You can buy or sell BMY and other stocks, options, ETFs, and crypto commission-free!

About

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. Read More The company was founded in August 1933 and is headquartered in New York, NY.

Employees
23,300
Headquarters
New York, New York
Founded
1933
Market Cap
80.55B
Price-Earnings Ratio
16.25
Dividend Yield
3.10
Average Volume
10.51M
High Today
$49.70
Low Today
$48.55
Open Price
$49.70
Volume
5.75M
52 Week High
$66.99
52 Week Low
$44.30

Collections

Pharmaceutical
Biopharmaceutical
Manufacturing
Research And Development
Health
Biotechnology
Technology
Business Services

News

Yahoo Finance7h

Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $49.21, moving -0.78% from the previous trading session. This move lagged the S&P 500's daily loss of 0.29%. Meanwhile, the Dow lost 0.55%, and the Nasdaq, a tech-heavy index, added 0.07%. Coming into today, shares of the biopharmaceutical company had lost 3.43% in the past month. In that same time, the Medical sector gained 2.03%, while the S&P 500 gained 2.14%. BMY will be looking to display strength as it nears its next earnings release, ...

42
Seeking Alpha8h

Celgene Presents An Attractive Short-Term Investment Opportunity In March 2019

The proposed cash and stock acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) saw the former's share price jump up from $66.64 on January 2 to $80.43 on January 3. Bristol-Myers Squibb has offered a total consideration of around $74 billion for Celgene.

161
The Motley FoolMar 19

Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?

It doesn't look as if Bristol-Myers Squibb (NYSE:BMY) sought approval from its largest shareholders before offering Celgene (NASDAQ:CELG) a whopping $90 billion earlier this year.

293

Earnings

$0.67
$0.81
$0.95
$1.09
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available Apr 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.